A network meta-analysis of the efficacy of inhaled antibiotics for chronic Pseudomonas infections in cystic fibrosis  by Littlewood, Kavi J. et al.
Journal of Cystic Fibrosis 11 (2012) 419–426
www.elsevier.com/locate/jcfOriginal Article
A network meta-analysis of the efﬁcacy of inhaled antibiotics for chronic
Pseudomonas infections in cystic ﬁbrosis
Kavi J. Littlewood a,⁎, Kyoko Higashi a, Jeroen P. Jansen b, Gorana Capkun-Niggli c,
Maria-Magdalena Balp c, Gerd Doering d, Harm A.W.M. Tiddens e, Gerhild Angyalosi c
a Mapi Consultancy, De Molen 84, 3995 AX Houten, The Netherlands
b Mapi Consultancy, 180 Canal Street, Suite 503, Boston MA 02114 United States
c Novartis Pharma AG, Postfach, CH-4002 Basel, Switzerland
d Institut für Medizinische Mikrobiologie und Hygiene, Wilhelmstr. 31, 72074 Tübingen, Germany
e Departments of Pediatric Pulmonology and Radiology, Erasmus MC-Sophia Children's Hospital, Dr. Molewaterplein 60, 3015 GJ, Rotterdam, The Netherlands
Received 27 January 2012; accepted 26 March 2012
Available online 19 June 2012Abstract
Background: Various inhaled antibiotics are currently used for treating chronic Pseudomonas aeruginosa lung infection in cystic ﬁbrosis (CF)
patients, however their relative efﬁcacies are unclear. We compared the efﬁcacy of the inhaled antibiotics tobramycin (TIP, TIS-T, TIS-B),
colistimethate sodium (colistin) and aztreonam lysine for inhalation (AZLI) based on data from randomised controlled trials.
Methods: In the base case, efﬁcacies of antibiotics were compared using a network meta-analysis of seven trials including change from baseline in
forced expiratory volume in 1 second (FEV1) % predicted, P. aeruginosa sputum density and acute exacerbations.
Results: The tobramycin preparations, AZLI and colistin, showed comparable improvements in efﬁcacy in terms of FEV1% predicted at 4 weeks;
the difference in % change from baseline (95%CrI) for TIP was compared to TIS-T (-0.55, -3.5;2.4), TIS-B (-0.64, -7.1;5.7), AZLI (3.64, -1.0;8.3)
and colistin (5.77, -1.2;12.8).
Conclusion: We conclude that all studied antibiotics have comparable efﬁcacies for the treatment of chronic P. aeruginosa lung infection in CF.
© 2012 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic ﬁbrosis; Pseudomonas aeruginosa; Inhaled antibiotics; Tobramycin; Network metaanalysis1. Introduction
Cystic fibrosis (CF) is the most common fatal inherited disease
among Caucasians, affecting approximately 80,000 individuals in
Europe and North America [1]. CF is characterised by chronic lung
infections with opportunistic pathogens [2] due to the conse-
quences of mutations in the CF transmembrane conductance
regulator (CFTR) gene [3] which compromise innate immune
functions [4]. Respiratory infections with P. aeruginosa are
recognised as having the largest impact onmorbidity andmortality.
Improved antibiotic strategies against respiratory tract infections
are considered the main reason for the increased life expectancy in⁎ Corresponding author at: De Molen 84, 3995 AX, Houten, The Netherlands.
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doi:10.1016/j.jcf.2012.03.010CF patients in the last decades. Particularly, early eradication
antibiotic therapy has successfully eradicated P. aeruginosa from
CF airways for considerable time periods and delayed onset of
chronic infection in many European CF centres in the last two
decades [5]. However, once established, chronic P. aeruginosa
infections are difficult to treat with antibiotics and the pathogen is
virtually never eradicated due to biofilm formation [5]. Therefore,
clinical trials of antibiotics for chronic P. aeruginosa lung infection
in individuals with CF use endpoints such as relative increase in
lung function and reduction of P. aeruginosa sputum density or
acute exacerbations rather than pathogen eradication. However,
while there are a number of antibiotics available which have been
used in the past to treat individuals with CF with chronic P.
aeruginosa infections, there is a paucity of data comparing the
efficacy and safety of these treatments to each other which would
guide the CF clinician.by Elsevier B.V. All rights reserved.
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tobramycin, colistimethate sodium and aztreonam lysine, using
a network meta-analysis (NMA). In the absence of head to head
trials against all comparators, NMA methods allow assessment
of relative efficacy in a structured and objective way [6,7]. We
assessed the endpoints; % change from baseline (CFB) in
forced expiratory volume in 1 second (FEV1) % predicted, CFB
of P. aeruginosa sputum density and exacerbations. Previously,
a Cochrane review [18] was conducted on inhaled antibiotics
for CF. However; a meta-analysis was, at that time, not
conducted judging study designs and reporting of results too
variable.2. Methods
2.1. Antibiotic formulations
The following approved antibiotic formulations for inhalation
were compared in this study: (i) tobramycin inhalation powder
capsule (TIP), containing 112 mg tobramycin BID (TOBI
Podhaler®), (ii) tobramycin inhalation solution (TIS-T), containing
300 mg/5 ml tobramycin BID (TOBI®), (iii) tobramycin inhalation
solution (TIS-B), containing 300 mg/4 ml tobramycin BID
(Bramitob®), (iv) colistimethate sodium (colistin), containing
80 mg/3 ml colistimethate sodiumBID (Colomycin®, Promixin®),
and (v) aztreonam lysine inhalation solution (AZLI), containing
75 mg aztreonam lysine TID (Cayston®).2.2. Identification and selection of studies
A systematic literature review was conducted for English
language publications in Medline, Medline in Process, Embase
and the Cochrane Library. Search terms included free-text and
thesaurus terms for cystic fibrosis, Pseudomonas, the interven-
tions of interest and randomised controlled study design. The
search was conducted on October 2010 and two publications of
the two TIP trials were added in January 2011. Conference data
from 2009 and 2010 were screened in BIOSIS and from the
European CF Conference, North American CF Conference,
European Respiratory Society and American Thoracic Society.
Two reviewers independently screened first the abstracts, then
selected full papers against the following predefined inclusion
criteria: (1) population: CF patients aged 6 years or older with
chronic P. aeruginosa infection; (2) interventions: inhaled
tobramycin, colistin, AZLI, amikacin or ciprofloxacin; (3)
comparisons: interventions above (at licensed dose) to each
other or placebo; (4) outcomes: percent CFB in FEV1% predicted
at 4 weeks and 20 weeks, CFB in P. aeruginosa sputum density
(measured by Log10 CFUs) at 4 weeks and 20 weeks, percent of
patients with use of additional anti-P. aeruginosa antibiotics
(intravenous, oral or inhaled) and percent of patients with at least
one hospitalisation for acute respiratory events within 24 weeks;
and (5) study design: randomised controlled trials in full
publications or from conferences (if sufficient data were
presented).2.3. Data extraction and validity assessment
For included studies, data were extracted on study design,
population, interventions, and outcomes described above. In cases
where CFBs of FEV1% predicted were not reported, data were
calculated from reported data, or else extracted from figures using
Digitizit software version 1.5.8 (Share-it!, Cologne, Germany).
The standard error of the difference in percent CFB was extracted
where reported, or calculated (e.g. based on 95% confidence
interval or standard deviation). If there were insufficient data for
the calculations, an average standard deviation was calculated
from included studies in each analysis and combined with study-
specific sample sizes to estimate the study-specific standard error.
2.4. Network meta-analysis (NMA)
Bayesian NMA models were applied with non-informative
priors [6–8] to simultaneously synthesize the results of included
studies and compare the efficacy and safety of antibiotics. The
outcome was the relative treatment effect of each intervention
versus placebo, and of TIP versus other comparators with a
probability of being the better treatment. Both fixed and random
effects models were evaluated. Fixed effects models assume one
true treatment effect, while random effects models allow for
different true treatment effects across studies, thus take account of
heterogeneity in relative treatment effects. The choice between a
fixed or random effects model for reported outcomes was based
on model fit criteria (Deviance Information Criteria (DIC)) which
penalise greater model complexity [8].
The NMA can synthesize a network of randomised controlled
trials (RCTs) and allow inferences about comparisons that have not
been studied in a head-to-head fashion. Even when direct evidence
is available for some treatments, combining this with indirect
comparisons in a NMA may yield a more refined and precise
estimate for the relative treatment effect [6,7]. Data on the
following outcomeswere analysed fromRCTs that were connected
via common comparators; changes in (i) FEV1% predicted, (ii) P.
aeruginosa sputum density and (iii) exacerbations (i.e. assessed by
respiratory hospitalisations or need for additional anti-P. aerugi-
nosa antibiotic use). Separate analyses for each outcome included
models for all available study data, various subgroups of studies
and/or inclusion of one of the following study-level covariates [9]
for possible effect modifiers that could bias results: mean baseline
age or mean baseline FEV1% predicted and mean percent of
patients with prior exposure to study drug. WinBUGS 1.4.1
statistical software was used for the analyses [10].
3. Results
3.1. Study identification
The literature search identified 413 abstracts. Of these, 39 full
papers were included for full-text screening from which 11
potentially relevant trials were assessed for the NMA (Fig. 1).
Eight were placebo-controlled trials and three compared two
active drugs (Tables 1 and 2). The base case analysis included a
network of 7 trials (Fig. 2).
413 abstracts identified  
OVID = 166 
Cochrane = 115 
Conferences = 132 
39 for full text review
11 trials included*
(For TIP studies 2301 and 2302, study 
reports were included, as publications 
were only available after the search) 
374 excluded due to;
Population (131) 
Intervention (118) 
Comparison (7) 
Outcomes (48) 
Study design (51) 
Repeat abstracts (16) 
No data on comparator (3) 
24 excluded due to;
Intervention (5) 
Comparison (1) 
Study design (16) 
Unpublished data (1) 
Limited details (1 abstract) 
Fig. 1. Study selection flow diagram. *Oermann data was only available in a poster.
Table 1
Study characteristics of 11 identified inhaled antibiotic studies in patients with
CF.
Source Type of RCT Duration (weeks) Treatments
[23] *DB, PC, MC 24: 3 cycles** TIP 122 mg BID vs. PLA
[22] OL, MC 24 TIP 112 mg BID vs.
TIS-T 300 mg BID
[12] DB, PC, MC 24: 3 cycles TIS-T 300 mg/5 mL BID vs
PLA
[15] DB, PC (pilot) 24: 3 cycles TIS-T 300 mg/5 mL BID vs
PLA
[13] OL, MC 4 TIS-T 300 mg/5 mL BID vs.
Colistin 80 mg/3 mL BID
[11] DB, PC 13 Colistin 1 MU/3 ml BID vs.
PLA
[16] DB, PC, MC, PG 8: 1 cycle TIS-B 300 mg/4 ml BID vs.
PLA
[21] DB, PC, MC, PG 24: 3 cycles TIS-B 300 mg/4 ml BID vs
PLA
[24] DB, PC, MC 4+8 follow up AZLI 75 mg BID or TID vs
PLA BID or TID
[25] DB, PC, MC 4 AZLI 75 mg TID vs PLA TID
[17] OL, PC, MC 24: 3 cycles AZLI 75 mg TID vs.
TIS-T 300 mg BID
*Double blind (DB), placebo-controlled (PC), multi-centre (MC), open-label
(OL), parallel-group (PG), placebo (PLA), tobramycin inhalation powder
capsule (TIP), tobramycin inhalation solution 300 mg/5 ml (TIS-T), tobramycin
inhalation solution 300 mg/4 ml (TIS-B), colistimethate sodium (colistin),
aztreonam lysine for inhalation (AZLI), twice a day (BID), three times a day
(TID).**Cycle=4 weeks on/4 weeks off.
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All studies were published after 2006, except for studies by
Jensen [11], Ramsey [12] and Hodson [13] (Table 1). With the
exclusion of Jensen [11], the remaining studies were considered a
homogenous group regarding study publication date. Five studies
included a younger population (mean baseline age between 11
and 16 years), and six studies included an older population (mean
baseline age between 20 and 32 years). Mean baseline FEV1%
predicted was between 49.9 and 63.6 (i.e. moderate impairment
(GOLD 2008) [14]) in all studies except Nasr [15] (mean baseline
FEV1% predictedN80%) and Jensen [11] (mean baseline
FEV1% predictedN70%) where patients were considered to
have mild impairment. The Lenoir study [16] included a
mixture of chronically- and intermittently-infected CF patients
with P. aeruginosa infection; 24.1% and 16.7% of patients in the
TIS-B and placebo arms, respectively, had a first or intermittent
P. aeruginosa infection. Regarding prior exposure to study
(active) drug, six studies had primarily treatment naïve popula-
tions (i.e. the majority of patients had never been exposed to the
active drug before) and two studies had primarily exposed
populations (i.e. most patients had previously used the active
drug). In the Nasr [15] and Jensen [11] studies exposure status
was unknown, and in the Oermann study [17], one arm was
exposed and one arm naïve to the study drugs. Patients who are
maintained (previously exposed) on a nebulised antibiotic
treatment appear to reach a plateau in FEV1% predicted after
some time and do not show a great improvement if at all.
Table 2
Baseline characteristics of participants in the identified trials.
Source Treatment Randomised
population
Gender
(% male)
Mean
age (y)
Mean
FEV1%
predicted
Exposure
[23] a TIP 46 b 41.3% 13.4 54.7 Naïve
Placebo 49 b 46.9% 13.2 58.5 Naïve
[22] a TIP 308 55.5% 25.9 52.9 Exposed
TIS-T 209 55.0% 25.2 52.8 Exposed
[12] TIS-T 258 58% 20.8 49.9 Naïve
Placebo 262 50% 20.6 51.2 Naïve
[15] TIS-T 16 37.5% 11.8 95.7 Unknown
Placebo 16 37.5% 15.9 83.7 Unknown
[13] TIS-T 53 37.7% 21.3 55.4 Exposed
Colistin 62 51.6% 20.1 59.4 Exposed
[11] Colistin 20 50% 13.6 71 Unknown
Placebo 20 55% 14.7 79 Unknown
[16] TIS-B 29 51.7% 11.0 57.7 Naïve
Placebo 30 56.7% 14.2 59.8 Naïve
[21] TIS-B 161 c 55.3% 14.8 60.7 Naïve
Placebo 84 c 54.8% 14.7 63.6 Naïve
[24] AZLI 66 c 57.6% 24.1 55.4 Naïve
Placebo 76 c 59.2% 27.9 53.9 Naïve
[25] AZLI 80 60% 27.4 54.4 Naïve
Placebo 84 53.6% 31.7 54.8 Naïve
[17] AZLI 136 c 50% 25.8 52.3 Naïve
TIS-T 132 c 50% 25.1 52.2 Exposed
Study [16] included patients with a first or intermittent P. aeruginosa infection
a Studies 2301 and 2302, which corresponded to [23,22] respectively.
b Randomised for safety. Patients received at least one capsule of study drug,
c Intention to treat population. Cystic ﬁbrosis (CF), P. aeruginosa (Pa),
tobramycin inhalation powder capsule (TIP), tobramycin inhalation solution
300 mg/5 ml (TIS-T), tobramycin inhalation solution 300 mg/4 ml (TIS-B),
colistimethate sodium (colistin), aztreonam lysine for inhalation (AZLI), forced
expiratory volume in 1 second percentage (FEV1%).
TIP 
PLACEBO TIS-B TIS-T 
AZLI 
COLISTIN
[23]
[24], [25]
[21]
[22]
[12]
[13]
Fig. 2. The base case network of evidence. The network of studies that was
included in the base case analysis is shown. Lines between boxes indicate which
treatments were compared directly in a randomised controlled trial (RCT).
Numbers in brackets reveal references. Tobramycin inhalation powder capsule
(TIP), tobramycin inhalation solution 300 mg/5 ml (TIS-T), tobramycin
inhalation solution 300 mg/4 ml (TIS-B), colistimethate sodium (colistin),
aztreonam lysine for inhalation (AZLI).
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largest in patients who are naïve to the antibiotic. The population
in each study arm was classified as naïve or exposed to the active
ingredient tested, and within each trial there was consistency in
exposure status. The Oermann data [17], however, could not be
included in the analysis as the study arm populations differed
regarding naïve/exposed status.
3.3. Base case results using % CFB in FEV1% predicted at
4 weeks
The base case NMA combined individual study results from 7
of the 11 trials assessing % CFB in FEV1% predicted (Table 3).
The Lenoir study [16] was excluded because not all patients were
chronically-infected with P. aeruginosa [5]. The Oermann study
[17] was excluded because the study arm populations differed
regarding naïve/exposed status. The studies of Nasr [15] and
Jensen [11], where patients had mild FEV1 impairment, were
excluded. Among the 7 included studies, there was variation in
mean age (2 studiesb18 y vs. 5 studiesN18 y) and exposure status
(2 studies exposed vs. 5 studies naïve to the study drug). As such,
the base case included a covariate for exposure.
TIP and TIS-T were more efficacious than placebo in
improving % CFB in FEV1% predicted (Table 4). For TIS-B,AZLI and colistin, the point estimates suggested improvement in
% CFB in FEV1% predicted over placebo, although there was a
fair degree of uncertainty around the point estimates. Regarding the
treatment effect of TIP, point estimates suggested that TIP was
superior to colistin and AZLI and was comparable to TIS-T and
TIS-B; the level of uncertainty around point estimates, however,
suggested a comparable efficacy of all treatments. TIS-T and TIS-
B, as well as AZLI and colistin seem to offer a comparable
efficacy.
3.4. Scenario analysis results
Several scenario analyses were run with or without a covariate
for baseline age, exposure or baseline FEV1, and in naïve or
exposed subgroups or in different age subgroups: (1) The ‘No
EXP covariate’ scenario included all 7 studies without a covariate
for exposure; (2) The naïve subgroup included the 5 studies with
no prior exposure to active drug; (3) The exposed subgroup
included the 2 studies with previously exposed populations; (4)
Scenario mild FEV1 included the Nasr [15] and Jensen [11]
studies with baseline FEV1% predicted N70% and a covariate for
baseline FEV1; (5) ‘All ages— cov AGE’ scenario included all 7
studies with a covariate for age rather than for exposure status;
and (6) The subgroups for age either included the 2 studies with a
mean ageb18 years, or 5 studies with mean ageN18 years.
The effects of each intervention versus placebo were fairly
consistent across each scenario compared to the base case (Fig. 3).
The largest effects were seen for inhaled tobramycin (TIP, TIS-T
and TIS-B), followed by AZLI and colistin (Fig. 4). The base case
with no covariate scenario resulted in less uncertainty around
results. It was not possible to compare the age subgroups, due to
differences in comparators included in these subgroups, except for
TIP; the effect of TIP versus placebo was higher in the subgroup
with mean ageb18 years compared to N18 years. Due to the lack
of data, it was not possible to assess whether this difference
was driven by the age differences or the naïve/exposed status
differences.
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The naïve subgroup did not allow a comparison to colistin and
produced slightly greater differences in efficacy than the base case
results, which is in line with the larger%CFB in FEV1% predicted
observed in these studies compared to the exposed status studies.
The comparison of TIP to colistin was possible via the indirect
route TIP–TIS-T/TIS-T–colistin. Given the lack of comparators
in the exposed subgroup, it was difficult to compare it to naïve
subgroups. There was, however, a consistent trend across all
scenario analyses in the effect of TIP relative to alternatives; with
the largest benefits compared to placebo, colistin and AZLI, and
with comparable benefits to TIS-T and TIS-B (Fig. 4).
3.6. Scenario on impact of baseline FEV1% predicted
(Scenario 4)
A consistent trend to the base case was observed across all
FEV1 analyses for the effect of TIP relative to alternatives. As
Nasr [15] and Jensen [11] studies were small (≤40 patients)
these had less weighting in the network, and therefore a minor
impact on results.
3.7. Scenarios on impact of mean baseline age (Scenarios 5
and 6)
Compared to the base case analysis, adding a covariate for
age rather than exposure produced similar results but greater
uncertainty. The subgroup with mean ageb18 years included
all naïve patients, and only allowed a comparison between
TIP and TIS-B. The subgroup with mean ageN18 years
included a mix of naïve and exposed status studies but did not
include TIS-B in the network. Therefore comparisons betweenTable 3
Percent change from baseline in FEV1% predicted in cystic fibrosis patients treated w
Source Mean
age
Exposure % CFB (SE)
Placebo TIS-T TI
[23] a b18 y Naive 0.68 (2.81)
[22] a N18 y Exposed 3.60 (1.03)
[12] a N18 y Naive 0.07 (1.02) 11.85 (1.53)
[15] b b18 y Unknown 0.90 (9.14) 1.36 (6.24)
[13] a N18 y Exposed 6.70 (2.14)
[11] b b18 y Unknown −13.92 (14.37)
[16] a b18 y Naive 4.23 (5.65) 27
[21] c b18 y Naive 0.77 (2.02) 12
[24] c N18 y Naive −2.00 (1.00)
[25] c N18 y Naive −2.44 (1.33)
[17] d N18 y Naive and exposed 0.55 (1.42)
Excluded studies: [15] had mild FEV1 impairment, [11] had mild FEV1 impairment
included a non-chronic Pa infected population. Calculated data in italics (from mean
size).
Tobramycin inhalation powder capsule (TIP), tobramycin inhalation solution 3
colistimethate sodium (colistin), aztreonam lysine for inhalation (AZLI), percent c
expiratory volume in 1 second percentage (FEV1%).
a Randomised and treated population with no imputation of missing data.
b Per protocol population.
c Randomised and treated population with imputation using LOCF.
d Randomised and treated population, unknown imputation status.the b18 year and N18 year populations were limited by lack of
data. Overall, a consistent trend to the base case was observed
across all scenario analyses for the effect of TIP relative to
alternatives.
3.8. Other endpoints
There were insufficient data to produce reliable results for %
CFB in FEV1% predicted at 20 weeks, P. aeruginosa sputum
density at 20 weeks, respiratory hospitalisation and anti-P.
aeruginosa antibiotic use at 24 weeks. Only 3 studies reported
these outcomes, with differences across studies. i.e., mix of
naïve/exposed status and age groups, and limited comparisons
possible. Regarding P. aeruginosa sputum density at 4 weeks; 7
studies reported this outcome and comparisons were possible
between TIP, TIS-T, TIS-B, colistin and AZLI. For this outcome,
TIP was expected to have better outcomes than placebo, and
comparable outcomes to other active treatments. As this analysis
included the same studies as for FEV1 at 4 weeks, there was
variability across the studies due to age and exposure (Fig. 5). This
resulted in a lot of uncertainty around results, and the limited data
available made it difficult to draw conclusions. Subgroup analyses
were limited because they did not allow comparisons to all
treatments of interest, and the inclusion of a covariate to address the
underlying variability increased the uncertainty of the results.
4. Discussion
CF is a rare disease with few pivotal studies of inhaled
antibiotics, and limited data on direct comparisons of currently
available treatment options. NMA helps overcome the lack of
head to head trials against all comparators. NMA is a valid
accepted method to assess relative efficacy and providesith different antibiotics from data reported in trials and relative treatment effects.
Difference in
% CFB (SE)
S-B AZLI Colistin TIP
13.97 (2.81) 13.29 (3.97)
2.80 (1.20) −0.8 (1.58)
11.78 (1.84)
0.46 (11.07)
0.37 (2.44) −6.33 (3.25)
−5.63 (11.50) 8.29 (18.41)
.92 (4.34) 23.69 (7.12)
.97 (1.46) 12.2 (2.49)
4.50 (1.00) 6.5 (1.41)
8.03 (1.33) 10.47 (1.88)
8.35 (1.42) 7.8 (2.01)
and old study, [17] had inconsistency due to naive and exposed status, and [16]
CFB data or mean FEV1 at 4 weeks and baseline FEV1, SE from SD and sample
00 mg/5 ml (TIS-T), tobramycin inhalation solution 300 mg/4 ml (TIS-B),
hange from baseline (%CFB), standard error (SE), P. aeruginosa (Pa), forced
Table 4
Network meta-analysis results: Difference in % CFB in FEV1% predicted at 4 weeks in Cystic Fibrosis patients treated with different antibiotics.
Placebo TIS-T TIS-B AZLI Colistin TIP
% CFB in FEV1% predicted at 4 weeks, (95% CrL)
Placebo 0
TIS-T 13.47
(0.67, 26.29)
0
TIS-B 13.55
(-0.27, 27.3)
0.09
(-5.82, 6.06)
0
AZLI 9.28
(-3.76, 22.14)
-4.19
(-8.14, -0.21)
-4.28
(-9.68, 1.07)
0
Colistin 7.15
(-7.19, 21.49)
-6.32
(-12.61, -0.02)
-6.40
(-15.11, 2.18)
-2.13
(-9.58, 5.36)
0
TIP 12.92
(0.18, 25.73)
-0.55
(-3.50, 2.4)
-0.64
(-7.05, 5.74)
3.64
(-1.04, 8.26)
5.77
(-1.20, 12.75)
0
Tobramycin inhalation powder capsule (TIP), tobramycin inhalation solution 300 mg/5 ml (TIS-T), tobramycin inhalation solution 300 mg/4 ml (TIS-B),
colistimethate sodium (colistin), aztreonam lysine for inhalation (AZLI), percent change from baseline (%CFB), forced expiratory volume in 1 second percentage
(FEV1%), credible limit (CrL).
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NMA is limited by the quality of the data included. As
randomisation only holds within a trial but not across trials, it is
possible to have bias in indirect comparisons. In this study, we
made every effort to avoid bias by ensuring only comparable
trials, i.e. similar populations and study designs, were
combined. To further control for potential bias, we included
the following covariates to control effect modifiers in our
models: 1) exposure status; 2) baseline FEV1% predicted; and
3) age.
Five antibiotics were presented in 11 trials, with a large amount
of heterogeneity across studies (e.g. naïve/exposed status, mild/
moderate FEV1% predicted, age differences, publication date)
which hampered the analyses and resulted in relatively low
precision of the estimates. Controlling for both potential effect
modifiers (mean age and previous exposure to the study drug) wasFig. 3. Overview of network meta-analysis scenario results for change in lung func
include placebo. Fixed effects model (FEM), random effects model (REM), exposure
from baseline (%CFB), forced expiratory volume in 1 second percentage (FEV1%
300 mg/5 ml (TIS-T), tobramycin inhalation solution 300 mg/4 ml (TIS-B), colistimnot possible simultaneously in this small dataset. Therefore
scenarios on exposure were not able to control for age differences,
and vice versa. Despite these drawbacks, the analyses, based on
point estimates, suggested that all treatments provided an
improvement compared to placebo, and that tobramycin formula-
tions provided an improvement over AZLI or colistin. However,
credible limits were too large to make this statistically significant.
The difference in%CFB for TIP compared to placebo, colistin and
AZLI can be considered clinically meaningful, using a cut-off of
3.5% CFB in FEV1% predicted. Our results are comparable to the
conclusions of a previous Cochrane review [18]. However; a meta-
analysis was, at that time, not conducted judging study designs and
reporting of results too variable.
Prior exposure to active drug was identified as a key factor
affecting outcomes, yet, this was not typically reported in trials
as a predictive factor. Most trials involved the first use of thetion of different antibiotics versus placebo. Exposed subgroup network did not
status (EXP), forced expiratory volume (FEV), covariate (Cov), percent change
), tobramycin inhalation powder capsule (TIP), tobramycin inhalation solution
ethate sodium (colistin), aztreonam lysine for inhalation (AZLI).
Fig. 5. Overview of network meta-analysis scenario results for change in sputum density of TIP versus alternative antibiotics. Fixed effects model (FEM), random
effects model (REM), exposure status (EXP), forced expiratory volume (FEV), covariate (Cov), percent change from baseline (%CFB), forced expiratory volume in
1 second percentage (FEV1%), tobramycin inhalation powder capsule (TIP), tobramycin inhalation solution 300 mg/5 ml (TIS-T), tobramycin inhalation solution
300 mg/4 ml (TIS-B), colistimethate sodium (colistin), aztreonam lysine for inhalation (AZLI).
Fig. 4. Overview of network meta-analysis scenario results for change in lung function of TIP versus alternative antibiotics. Fixed effects model (FEM), Random
effects model (REM), exposure status (EXP), forced expiratory volume (FEV), covariate (Cov), percent change from baseline (%CFB), forced expiratory volume in
1 second percentage (FEV1%), tobramycin inhalation powder capsule (TIP), tobramycin inhalation solution 300 mg/5 ml (TIS-T), tobramycin inhalation solution
300 mg/4 ml (TIS-B), colistimethate sodium (colistin), aztreonam lysine for inhalation (AZLI).
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426 K.J. Littlewood et al. / Journal of Cystic Fibrosis 11 (2012) 419–426active drug, and therefore had a population who was naïve to
the active drug. The head to head studies were conducted after
approval of colistin and tobramycin, and therefore included a
population that was already exposed to these drugs. From the
data reported in trials, there was generally a larger gain in %
CFB in FEV1% predicted for naïve populations than for
exposed populations. More recent trials, such as the Oermann
study [17], are more likely to include exposed populations as
the majority of chronically-infected patients are now regularly
treated with inhaled tobramycin or colistin. The Oermann
study [17], however, included one arm with prior exposure to
the active drug (TIS-T) and one arm naïve to the active drug
(AZLI). Therefore the study design presented an inconsisten-
cy in the network by not comparing ‘like with like’. Objective
comparison between the treatments in this study was therefore
challenging.
Future trials and comparisons will increasingly need to consider
study design and population differences. Additional research is
needed on potential effect modifiers to understand their impact on
outcomes and their relative importance. One such example is chest
computed tomography to characterize structural lung abnormalities
at baseline [19,20]. Future studies should include a more
homogenous population regarding age, baseline FEV1% predicted
and inclusion of either chronically- or non-chronically-infected
patients. The major study design difficulty is in controlling for
exposure status as most patients today will have prior exposure to
several antibiotics. This field needs clinicians and researchers to
align the approach to study design, population selection and the
most relevant comparative outcomes.
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